A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Everolimus (Primary) ; Exemestane
- Indications Advanced breast cancer; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 30 Nov 2018 to 28 Jan 2019.
- 09 Jan 2019 Planned primary completion date changed from 30 Nov 2018 to 28 Jan 2019.